



 MedImpact Formulary


2025 Abridged Formulary Select EX

EFFECTIVE JANUARY 1, 2025



Copyright © 2024 MedImpact Healthcare Systems, Inc. All rights reserved.

This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.





2025 Abridged Formulary Select EX

Effective January 1, 2025

List of most commonly prescribed medications

The following is a list of the most commonly prescribed brand and generic medications. It represents an abbreviated version of the formulary list that is at the core of your prescription drug benefit plan. The list is not all-inclusive and does not guarantee coverage. Some preferred medications overlap with other clinical programs and may not be covered. In addition to drugs on this list, the majority of generic medications are covered under your plan and you are encouraged to ask your doctor to prescribe generic drugs whenever appropriate. The Pharmacy & Therapeutics (P&T) Committee is responsible for the development and maintenance of the formulary. The committee is comprised of independent practicing physicians and pharmacists from a wide variety of medical specialties. The formulary is reviewed and updated as new drugs or new prescribing information becomes available. Factors which affect decisions regarding the formulary include safe use, clinical efficacy and therapeutic need. Only after those factors are assessed is cost considered. Compliance with the formulary is important for improving quality of care and restraining health care costs. A copy of this formulary document is available at elixirsolutions.com. PLEASE NOTE: Preferred brand drugs may move to non-preferred status if a generic version becomes available during the year. Not all drugs listed are covered by all prescription drug benefit programs. Certain utilization edits and criteria may apply. For specific questions about your coverage, please visit elixirsolutions.com.

Effective 01/01/2025

A

ABILIFY ASIMTUFI	AKLIEF [NP]	ARCAPTA NEOHALER [NP]
ABILIFY MAINTENA	ALECENSA [SP]	ARIKAYCE [NP] [SP]
ACTHAR [NP] [SP]	ALINIA	ARNUITY ELLIPTA
ACTIMMUNE [SP]	ALORA [NP]	ASMANEX
ADALIMUMAB-ADAZ [SP]	ALPROLIX [SP]	ASTAGRAF XL [NP]
ADBRY [SP]	ALUNBRIG [SP]	ATROVENT HFA [NP]
ADDYI [NP]	AMZEEQ [NP]	AUGMENTIN [NP]
ADEMPAS [NP] [SP]	ANGELIQ [NP]	AURYXIA [NP]
ADVAIR HFA	ANORO ELLIPTA	AUSTEDO
ADVATE [SP]	APADAZ [NP]	AUSTEDO XR [SP]
ADYNOVATE [SP]	APOKYN [NP] [SP]	AUVELITY [NP]
AFSTYLA [SP]	APTIOM	AUVI-Q
AIMOVIG	APTIVUS [NP]	AVONEX [SP]
AIRSUPRA	ARAKODA [NP]	AVSOLA [SP]
AJOVY	ARANESP [SP]	AYVAKIT [SP]
	ARCALYST [NP] [SP]	AZSTARYS

[NP] = Non-Preferred

[SP] = Specialty



2025 Abridged Formulary Select EX

Effective January 1, 2025

B

BALVERSA [NP] [SP]
BAQSIMI
BARACLUDE
BAXDELA [NP]
BECONASE AQ [NP]
BELBUCA
BELSOMRA
BENEFIX [SP]
BENLYSTA [NP] [SP]
BERINERT [NP] [SP]
BESIVANCE
BETASERON [SP]
BEYFORTUS
BIJUVA
BIKTARVY
BIMZELX [NP] [SP]
BLEPHAMIDE [NP]
BONJESTA [NP]
BOSULIF [SP]
BRAFTOVI [NP] [SP]
BREO ELLIPTA
BREZTRI AEROSPHERE
BRILINTA
BRIVIACT
BRIXADI [NP]
BROMSITE [NP]
BRUKINSA [SP]
BYDUREON
BYETTA

C

CABLIVI [NP] [SP]
CABOMETYX [SP]
CALQUENCE [SP]
CAPRELSA [SP]
CARAC
CAVERJECT [NP]

CAYSTON [NP] [SP]
CERDELGA [SP]
CERVIDIL [NP]
CHEMET
CHENODAL [SP]
CHOLBAM [NP] [SP]
CIMDUO
CIMZIA [NP] [SP]
CLINDESSE [NP]
COAGADEX [SP]
COARTEM [NP]
COMBIPATCH
COMBIVENT RESPIMAT
COMETRIQ [SP]
COMPLERA [NP]
COPAXONE 40MG [SP]
COPIKTRA [NP] [SP]
CORIFACT [SP]
CORTIFOAM
COSENTYX [SP]
COTELLIC [SP]
CREON
CRESEMBA [NP]
CRINONE
CRIXIVAN [NP]
CYCLOMYDRIL [NP]
CYSTADROPS [NP] [SP]
CYSTAGON [SP]
CYSTARAN [NP] [SP]

D

DAURISMO [NP] [SP]
DELSTRIGO
DEPO-ESTRADIOL [NP]
DESCOVY

DEXCOM G6 and G7
DIACOMIT [NP]

DIFICID
DILANTIN [NP]
DOPTELET [SP]
DOVATO
DROXIA [NP]
DUAVEE
DULERA
DUOBRII [NP]
DUOPA [NP] [SP]
DUPIXENT [SP]
DUROLANE

E

EDEX [NP]
EDURANT [NP]
ELESTRIN [NP]
ELIGARD [SP]
ELIQUIS
ELLA
ELMIRON [NP]
ELOCTATE [SP]
ELYXYB [NP]
EMCYT [SP]
EMEND
EMGALITY
EMPAVELI [NP] [SP]
EMSAM [NP]
EMTRIVA [NP]
ENBREL [SP]
ENCARE
ENSPRYNG [NP] [SP]
ENSTILAR
ENTRESTO
ENTYVIO PEN [NP] [SP]
ENVARUS XR [NP]
EPCLUSA [SP]
EPIDIOLEX [SP]
EPIVIR HBV [NP]

[NP] = Non-Preferred

[SP] = Specialty



2025 Abridged Formulary Select EX

Effective January 1, 2025

EQUETRO [NP]
ERGOMAR [NP]
ERIVEDGE [SP]
ERLEADA [SP]
ERMEZA [NP]
ESPEROCT [SP]
ESTRING
ESTROGEL
ETOPOSIDE [SP]
EUCRISA
EUFLEXXA
EVAMIST [NP]
EVERSENSE [NP]
EVOTAZ
EVRYSDI [NP] [SP]
EYSUVIS

F

FABHALTA [SP]
FANAPT [NP]
FARXIGA FARYDAK [SP]
FASENRA PEN [SP]
FEIBA [SP]
FEMCAP
FETZIMA
FIASP
FINTEPLA [NP] [SP]
FIRDAPSE [NP] [SP]
FIRVANQ [NP]
FLAREX [NP]
FOLLISTIM AQ [NP] [SP]
FOSRENOL [NP]
FOTIVDA [NP] [SP]
FRAGMIN [NP]
FREESTYLE LIBRE
FUZEON [NP]
FYCOMPA
FYLNETRA [NP] [SP]

G

GALAFOLD [NP] [SP]
GALZIN [NP]
GAMMAGARD [SP]
GAMMAPLEX [SP]
GATTEX [NP] [SP]
GAVRETO [NP] [SP]
GELSYN-3
GEMTESA [NP]
GENOTROPIN [SP]
GENVOYA
GILOTRIF [SP]
GLASSIA [NP] [SP]
GLEOSTINE [SP]
GLUCAGEN HYPOKIT [NP]
GLYXAMBI
GONAL [SP]
GUARDIAN 3 and 4
PRODUCTS [NP]
GRASTEK [NP]
GVOKE

H

HAEGARDA [NP] [SP]
HARVONI [SP]
HEMANGEOL
HEMLIBRA [SP]
HEMOFIL M [SP]
HUMATE-P [SP]
HUMIRA [SP]
HUMULIN R U-500
HYCAMTIN [SP]

I

IBRANCE [NP] [SP]
ICLUSIG [SP]
IDELVION [SP]
IDHIFA [NP] [SP]

ILET PRODUCTS [NP]
ILEVRO [NP]
IMBRUVICA [SP]
IMCIVREE [NP] [SP]
IMPAVIDO [SP]
INBRIJA [SP]
INCRELEX [SP]
INCRUSE ELLIPTA
INGREZZA [SP]
INLYTA [SP]
INQOVI [NP] [SP]
INREBIC [NP] [SP]
INTELENCE
INTRON A [SP]
INVEGA HAFYERA
INVEGA SUSTENNA
INVEGA TRINZA
INVIRASE [NP]
IRESSA [SP]
ISENTRESS
ISENTRESS HD
ISTURISA [NP] [SP]
IXINITY [SP]

J

JAKAFI [SP]
JANUMET
JANUMET XR
JANUVIA
JARDIANCE
JAYPIRCA [NP] [SP]
JIVI [SP]
JORNAY PM
JUBLIA
JULUCA
JUXTAPID [NP] [SP]
JYNARQUE [NP] [SP]

[NP] = Non-Preferred

[SP] = Specialty



2025 Abridged Formulary Select EX

Effective January 1, 2025

K

KALYDECO [SP]
KERENDIA [NP]
KESIMPTA [SP]
KEVZARA [NP] [SP]
KISQALI [SP]
KLISYRI [NP]
KLOXXADO
KOSELUGO [NP] [SP]
KOVALTRY [SP]
KRINTAFEL [NP]
KYLEENA
KYNMOBI

L

LAMPIT [NP]
LANTUS
LENVIMA [SP]
LEUKERAN [SP]
LEUKINE [NP] [SP]
LEUPROLIDE [SP]
LINZESS
LITFULO [NP] [SP]
LO LOESTRIN FE
LOKELMA
LOMAIRA [NP]
LONSURF [SP]
LORBRENA [NP] [SP]
LOTEMAX
LUMIGAN
LUPANETA PACK [NP] [SP]
LUPKYNIS [NP] [SP]
LUPRON DEPOT [SP]
LUPRON DEPOT-PED [SP]
LYNPARZA [SP]
LYSODREN [SP]

M

MARPLAN [NP]
MATULANE [SP]
MAVENCLAD [SP]
MAVYRET [SP]
MAXIDEX [NP]
MAYZENT [SP]
MEKINIST [SP]
MEKTOVI [NP] [SP]
MENEST [NP]
MENOPUR [NP] [SP]
MENOSTAR [NP]
MESNEX
METHITEST [NP]
MIEBO
MIGERGOT [NP]
MINIMED PRODUCTS [NP]
MIRENA
MOUNJARO
MOVANTIK
MULPLETA [SP]
MULTAQ
MYALEPT [NP] [SP]
MYCAPSSA [NP] [SP]
MYFEMBREE
MYLERAN [SP]
MYRBETRIQ
MYTESI [NP]

N

NATACYN
NATAZIA [NP]
NATPARA [NP] [SP]
NATROBA [NP]
NAYZILAM [NP]
NERLYNX [NP] [SP]
NEUPRO [NP]
NEXLETOL

NEXLIZET
NICOTROL
NINLARO [SP]
NITRO-BID [NP]
NITYR [SP]
NIVESTYM [SP]
NORDITROPIN FLEXPPO [SP]
NORVIR
NOVAREL [SP]
NOVOLIN 70/30
NOVOLIN N
NOVOLIN R
NOVOLOG
NOVOLOG MIX 70/30
NOVOPEN ECHO
NOXAFIL
NUBEQA [SP]
NUCALA [SP]
NUCYNTA ER
NUEDEXTA
NULIBRY [NP] [SP]
NURTEC
NUVESSA [NP]
NUWIQ [SP]
NUZYRA [NP]
NYMALIZE [NP]

O

OBIZUR [SP]
OCALIVA [NP] [SP]
OCTAGAM [SP]
ODACTRA [NP]
ODEFSEY
ODOMZO [SP]
OFEV [NP] [SP]
OLUMIANT [NP] [SP]
OMNARIS [NP]
OMNIPOD

[NP] = Non-Preferred

[SP] = Specialty



2025 Abridged Formulary Select EX

Effective January 1, 2025

OMNIPOD-GO
OMNITROPE [NP] [SP]
ONETOUCH TEST PRODUCTS
ONEXTON
ONUREG [NP] [SP]
OPSUMIT [SP]
ORACEA
ORALAIR [NP]
ORAVIG [NP]
ORENITRAM [NP] [SP]
ORFADIN [SP]
ORGOVYX [NP] [SP]
ORIAHNN
ORILISSA
ORKAMBI [NP] [SP]
ORLADEYO [NP] [SP]
OTEZLA [SP]
OTREXUP
OXBRYTA [NP] [SP]
OXERVATE [NP] [SP]
OXYCONTIN
OVIDREL [SP]
OZEMPIC

P

PALFORZIA [NP]
PALYNZIQ [NP] [SP]
PANZYGA [SP]
PAXLOVID [NP]
PAZEO
PEGASYS [SP]
PEGINTRON [NP] [SP]
PEMAZYRE [NP] [SP]
PERSERIS
PHOSLYRA [NP]
PHOSPHOLINE [NP] [SP]
PIQRAY [SP]
PLEGRIDY [SP]

POMALYST [SP]
PREFEST [NP]
PREGNYL [NP] [SP]
PREMARIN
PREMPHASE
PREMPRO
PRETOMANID [NP]
PREVYMIS [NP]
PREZCOBIX
PREZISTA
PRIFTIN
PRIVIGEN [SP]
PROCTOFOAM HC [NP]
PROCYSBI [NP] [SP]
PROGRAF [NP]
PROLASTIN-C [SP]
PROMACTA [SP]
PULMOZYME [SP]
PURIXAN

Q

QBRELIS [NP]
QELBREE [NP]
QINLOCK [NP] [SP]
QNASL [NP]
QTERN [NP]
QUILLICHEW ER
QUILLIVANT XR
QULIPTA
QVAR REDIHALER

R

RAGWITEK [NP]
RAYALDEE [NP]
REBIF [SP]
REDITREX
REGRANEX [NP]
RELENZA DISKHALER [NP]
RELISTOR [NP]

REPATHA
RESTASIS
RETACRIT [SP]
RETEVMO [SP]
REVCOSI [SP]
REVLIMID [SP]
REXULTI
REYATAZ [NP]
REYVOW
RHOFAD [NP]
RHOPRESSA [NP]
RIDAURA [NP]
RINVOQ [SP]
RINVOQ LQ [SP]
RIXUBIS [SP]
ROCKLATAN [NP]
ROSZET [NP]
ROZLYTREK [SP]
RUBRACA [SP]
RUCONEST [NP] [SP]
RUKOBIA [NP]
RYBELSUS
RYDAPT [SP]
RYKINDO
RYTARY [NP]

S

SANTYL [NP]
SAXENDA
SECUADO [NP]
SEREVENT DISKUS
SCEMBLIX [SP]
SFROWASA [NP]
SIGNIFOR [NP] [SP]
SIKLOS [NP]
SIMBRINZA
SIMLANDI [SP]
SIMPONI [NP][SP]

[NP] = Non-Preferred

[SP] = Specialty



2025 Abridged Formulary Select EX

Effective January 1, 2025

SIRTURO [NP] [SP]
SIVEXTRO [NP]
SKYLA
SKYRIZI [SP]
SKYTROFA [SP]
SODIUM OXYBATE [NP] [SP]
SOGROYA [SP]
SOLIQUA
SOLOSEC
SOLTAMOX
SOMAVERT [NP] [SP]
SOTYKTU] [SP]
SOVALDI [SP]
SPIRIVA RESPIMAT
SPRITAM [NP]
STELARA [SP]
STIMATE
STIOLTO RESPIMAT
STIVARGA [SP]
STRENSIQ [SP]
STRIBILD [NP]
STRIVERDI RESPIMAT
SUBSYS [NP]
SUCRAID [NP] [SP]
SUNOSI
SUPARTZ FX
SUPRAX
SUTENT [SP]
SYMDEKO [SP]
SYMPROIC
SYMTUZA
SYNAREL [SP]
SYNJARDY
SYNJARDY XR
SYNRIBO [SP]
SYNTHROID

T
TABLOID [SP]
TABRECTA [SP]
TAFINLAR [SP]
TAGRISSO [SP]
TAKHZYRO [NP] [SP]
TALICIA
TALZENNA [SP]
TASIGNA [SP]
TAVALISSE] [SP]
TAZVERIK [NP] [SP]
TEGSEDI [NP] [SP]
TEMIXYS
TEPMETKO [NP] [SP]
TEZPIRE [SP]
THALOMID [SP]
THEO-24 [NP]
THIQUIDITY [NP]
TIBSOVO [NP] [SP]
TIROSINT SOLN [NP]
TIVICAY
TLANDO [NP]
TOBI PODHALER [SP]
TOBRADEX ST [NP]
TOUJEO SOLOS
TRACLE ER [SP]
TRECATOR [NP]
TRELEGY ELIPTA
TREMIFYA [SP]
TRESIBA
TRETEN [SP]
TRIJARDY XR
TRIKAFTA [SP]
TRINATE
TRINTELLIX
TRIUMEQ
TRIUMEQ PD

TRULANCE
TRULICITY
TUKYSA [NP] [SP]
TURALIO [NP] [SP]
TYBOST [NP]
TYENNE [NP] [SP]
TYMLOS [SP]
TYRVAYA
TYVASO [NP] [SP]

U
UBRELVY
UCERIS [NP]
UDENYCA ONBODY [NP] [SP]
UPTRAVI
UZEDY

V
VALCHLOR [SP]
VALTOCO [NP]
VARUBI
VASCEPA
VECAMYL [NP] [SP]
VELPHORO
VELTASSA [NP]
VEMLIDY
VENCLEXTA [SP]
VENTAVIS [NP] [SP]
VEOZAH [NP]
VERQUOVO
VERSACLOZ [NP]
VERZENIO [SP]
V-GO
VIBERZI
VIRACEPT [NP]
VIREAD
VITRAKVI [SP]
VIVOTIF [NP]
VIZIMPRO [NP] [SP]

[NP] = Non-Preferred

[SP] = Specialty



2025 Abridged Formulary Select EX

Effective January 1, 2025

VONVENDI [SP]
VOQUENZA [NP]
VOSEVI [SP]
VRAYLAR [NP]
VTAMA [NP]
VUMERITY [SP]
VYLEESI [NP]
VYNDAMAX [SP]
VYNDAQEL [SP]
VYZULTA [NP]

W

WEGOVY
WILATE [SP]
WINLEVI [NP]
WINREVAIR [SP]

X

XALKORI [SP]
XARELTO
XCOPRI
XELJANZ [SP]
XELJANZ XR [SP]
XENICAL [NP]
XENLETA [NP]
XEPI [NP]
XERMELO [NP] [SP]
XHANCE
XIFAXAN [NP]
XIGDUO XR
XIIDRA
XOFLUZA [NP]
XOLAIR [SP]
XOSPATA [NP] [SP]
XPOVIO [NP] [SP]
XTAMPZA ER
XTANDI [SP]
XULTOPHY
XYNTHA [SP]

XYWAV [NP] [SP]

Y

YONSA [SP]

Z

ZEGALOGUE
ZEJULA [SP]
ZELBORAF [SP]
ZENPEP
ZEPOUND
ZEPOZIA [NP] [SP]
ZETONNA [SP]
ZIEXTENZO [SP]
ZILXI
ZOKINVY [SP]
ZOLINZA [SP]
ZONTIVITY [NP]
ZORTRESS [NP]
ZUBSOLV [NP]
ZURZUVAE [SP]
ZYCLARA PUMP
ZYDELIG [SP]
ZYKADIA [SP]
ZYLET [NP]

[NP] = Non-Preferred

[SP] = Specialty



2025 Abridged Formulary Select EX

Effective January 1, 2025

Excluded Medications with Covered Alternatives

THERAPEUTIC CATEGORY	FORMULARY ALTERNATIVE	FORMULARY EXCLUSION
ANTIINFECTIVES		
Antibacterial Agents	Clindesse, clindamycin 2% cream	Xacianto
Antifungal Agents (Oral)	fluconazole, terconazole	Brexafemme, Vivjoa
Antiretrovirals	abacavir sulfate/lamivudine, Cimduo, Descovy, Dovato, emtricitabine/tenofovir disoproxil fumarate, Evotaz, Juluca, lamivudine/zidovudine, lopinavir/ritonavir, Prezcoibix, Temixys	Cabenuva ¹
Helicobacter Pylori Infection	amoxicillin/clarithromycin/lansoprazole	Voquezna Dual Pak, Voquezna Triple Pak
AUTONOMIC & CENTRAL NERVOUS SYSTEM		
Acute Migraine-CGRP nasal	Nurtec, sumatriptan nasal, Ubrelvy	Zavzpret
Anti-Migraines	generic dihydroergotamine, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan	Trudhesa
Anti-Parkinsonism Agents	carbidopa/levodopa, carbidopa/levodopa ER	Crexont, Dhivy
Anticonvulsants	Aptiom, Briviact, lacosamide, Oxtellar, phenytoin, zonisamide	Motpoly XR
	topiramate capsule, topiramate ER sprinkle	Elepsia, Eprontia
Antidepressants	Auvelity [NP], bupropion IR/ER, citalopram, desvenlafaxine, duloxetine, escitalopram, Fetzima, fluoxetine, paroxetine, sertraline, Trintellix, venlafaxine IR/ER, vilazodone	Aplenzin, Citalopram capsule, Venlafaxine 112.5 mg
Antipsychotics (Oral)	asenapine, aripiprazole, Cobenfy [NP], generic quetiapine, lurasidone, olanzapine, Rexulti, Vraylar [NP], ziprasidone	Caplyta, Latuda, Lybalvi, Quetiapine
Antipsychotics (Injectables)	Abilify Asimtufii, Abilify Maintena, Aristada, Invega Hafyera, Invega Sustenna, Invega Trinza, risperidone microspheres, Rykindo, Perseris, Uzedly	Risperdal Consta
Attention Deficit Hyperactivity Disorder (ADHD) – Amphetamine Products	amphetamine/dextroamphetamine, amphetamine/dextroamphetamine ER, lisdexamfetamine	Adderall, Adderall XR, Adzenys, Dyanavel XR, Evekeo ODT, Mydayis, Vyvanse, Xelstryl, Zenzedi

[SP] = All specialty brand drugs

¹ = Specific criteria may apply to the category

Brand drugs = Capitalized Generic drugs = lower case



2025 Abridged Formulary Select EX

Effective January 1, 2025

Excluded Medications with Covered Alternatives

THERAPEUTIC CATEGORY	FORMULARY ALTERNATIVE	FORMULARY EXCLUSION
Attention Deficit Hyperactivity Disorder (ADHD) – Miscellaneous Stimulants	Azstarys, dexamethylphenidate HCl/ER, Jornay PM, methylphenidate HCl/CD/ER, Quillichew ER, Quillivant XR	Adhansia XR, Aptensio XR, Concerta, Cotempla XR-ODT, Daytrana, Focalin/XR, Methylin, Relexxii, Ritalin, Ritalin LA
Fentanyl Analgesics ¹	fentanyl citrate oral, fentanyl transdermal patch, fentanyl transmucosal lozenge	Actiq, Duragesic
Multiple Sclerosis [SP*] ¹	Avonex, Betaseron, Copaxone 40 mg, Glatiramer, Glatopa, Kesimpta, Mavenclad, Mayzent, Plegridy, Rebif, Vumerity, Zeposia	Aubagio, Bafiertam, Briumvi, Copaxone 20 mg, Extavia, Gilenya, Ponvory, Tascenso ODT, Tecfidera
Narcolepsy [SP] ¹	Sunosi	Wakix
Narcolepsy: (Sodium oxybate) [SP*] ¹	sodium oxybate, Xywav	Lumryz, Xyrem
Narcotic Analgesics & Combinations	celecoxib, hydrocodone bitartrate ER, morphine sulfate ER, Oxycontin, tramadol, Xtampza ER	Hysingla ER, Seglentis
Opioid-Overdose	naloxone, Kloxxado	Opvee
Opioid Abuse – Treatment	buprenorphine HCl/naloxone HCl	Bunavail, Probuphine Implant Kit, Sublocade, Suboxone
Opioid Agonist – Pain	Belbuca	Butrans
Sleep Disorder (Insomnia)	Belsomra, eszopiclone, zolpidem tartrate tab, zolpidem tartrate ER	Ambien, Ambien CR, Edluar, Intermezzo, Lunesta, Quviviq, ramelteon, Zolpidem 7.5 mg cap, Zolpimist
CARDIOVASCULAR		
Anticoagulants	Eliquis, Xarelto	Pradaxa, Pradaxa Pak, Savaysa
Antihypertensives	candesartan, irbesartan, losartan, losartan/HCTZ, olmesartan, telmisartan, valsartan, valsartan/HCTZ,	Edarbi, Edarbyclor
Anti-Inflammatory	atorvastatin, rosuvastatin, simvastatin	Lodoco
Cholesterol – PCSK9 ¹	Repatha	Leqvio, Praluent
Cholesterol – Statins	atorvastatin, rosuvastatin, simvastatin	Atorvaliq
Pulmonary Arterial Hypertension – Prostacyclin [SP*] ¹	Tyvaso nebulizer	Tyvaso DPI
DERMATOLOGY		
Atopic Dermatitis [SP*] ¹	Adbry, Dupixent, Rivnoq	Cibinqo
Oral Acne	doxycycline hyclate, doxycycline monohydrate, minocycline HCl IR caps	Doryx MPC, minocycline ER caps, Minocin, Minolira, Seysara, Ximino

[SP] = All specialty brand drugs

¹ = Specific criteria may apply to the category

Brand drugs = Capitalized Generic drugs = lower case



2025 Abridged Formulary Select EX

Effective January 1, 2025

Excluded Medications with Covered Alternatives

THERAPEUTIC CATEGORY	FORMULARY ALTERNATIVE	FORMULARY EXCLUSION
Plaque Psoriasis	Betamethasone, Enstilar, tazarotene cream, tazarotene gel, Vtama [NP]	Tazorac cream 0.1%, Tazorac cream 0.5%, Tazorac gel, Zoryve
Rosacea	ivermectin, metronidazole	Doxycycline capsule DR 40 mg, Epsolay
Topical Acne	Avita, tretinoin	Retin-A, Twynoe
Topical Actinic Keratosis	Carac, fluorouracil, imiquimod	Aldara, Tolak
DIABETES		
Biguanides	Metformin, Metformin ER	Fortamet, Glumetza
Diabetes – Testing Supplies	Freestyle, Precision, OneTouch Products	All Other Meters and Test Strips
Diabetes - CGM	Dexcom G6/G7, Freestyle Libre 1, 2 & 3	Enlite, Eversense E3, Guardian Connect, Minilink, Paradigm
Dipeptidyl Peptidase-4 Inhibitors & Combinations	Janumet, Janumet XR, Januvia	Alogliptin, Jentadueto, Jentadueto XR, Onglyza, Tradjenta
Sodium-Glucose Cotransporter-2 Inhibitors	Farxiga, Jardiance, Synjardy, Synjardy XR, Xigduo XR	Brenzavvy, Invokamet, Invokamet XR, Invokana, Inpefa, Segluromet, Steglatro, Steglujan
Glucagon-Like Polypeptide 1 Agonists	Bydureon, Byetta, Mounjaro, Ozempic, Rybelsus, Trulicity	Adlyxin, Victoza
Insulin – Intermediate Acting	Humulin U-500, Novolin N	Humulin N
Insulin – Long Acting	Lantus, Toujeo, Tresiba	Basaglar, Insulin Degludec, Insulin Glargine, Insulin Glargine-yfgn, Rezvoglar, Semglee
Insulin – Rapid Acting	Fiasp, Novolog	Admelog, Afrezza, Apidra, Humalog, Insulin Aspart, Insulin Lispro, Lyumjev
ENDOCRINE		
CKD Agent -Phosphate Binder	Auryxia [NP], sevelamer, Velphoro	Xphozah
Contraceptives – Combinations	drospirenone/ethinyl estradiol, Generic Beyaz, Generic Safyral, Generic Yaz	Beyaz, Chateal, , Nuvaring, Ortho-Novum 1/35, Safyral, Yasmin 28, Yaz
Contraceptives – Progestins	Camila, Errin, Heather, Lyza	Ortho Micronor
Estrogen and Estrogen Modifiers for Vaginal Symptoms	estradiol, Estring, Yuvaferm	Femring, Imvexxy, Vagifem
Gonadotropin Releasing Hormone [SP*]	Agonist Eligard, Firmagon	Camcevi
Growth Hormone [SP*] ¹	Genotropin, Norditropin,	Humatrope, Saizen, Nutropin, Zomacton
Growth Hormone [SP*] ¹	Skytrofa, Sogroya	Ngenla
Menopause	Combipatch	Climara Pro
Osteoporosis [SP*] ¹	teriparatide, Tymlos	Forteo, Teriparatide (NDC 47781065289)

[SP] = All specialty brand drugs

¹ = Specific criteria may apply to the category

Brand drugs = Capitalized Generic drugs = lower case



2025 Abridged Formulary Select EX

Effective January 1, 2025

Excluded Medications with Covered Alternatives

THERAPEUTIC CATEGORY	FORMULARY ALTERNATIVE	FORMULARY EXCLUSION
Testosterone ¹	testosterone cypionate, testosterone enanthate, Tlando [NP]	Androgel, Fortesta, Jatenzo, Kyzatrex
EPINEPHRINE AUTO-INJECTOR SYSTEMS		
Anaphylaxis	Auvi-Q, epinephrine	Adrenalin, Epipen, Epipen-JR, Symjepi
GASTROINTESTINAL		
Anticholinergics	esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole	Dartisla ODT
Bowel Prep	Gavilyte, PEG-3350/NACL/NA/Bicarb/KCL, Trilyte	Suflave
Irritable Bowel Syndrome & Opioid Induced Constipation	Linzess, Movantik, Symproic, Trulance	Amitiza, Ibsrela, Motegrity, Relistor solution, Relistor tablets, Zelnorm
Proton Pump Inhibitors	Nexium Packet, omeprazole suspension	Konvomep
HEMATOLOGICAL AGENTS		
Erythropoiesis-Stimulating Agents [SP*] ¹	Retacrit	Epogen, Jesduvroq, Procrit
Granulocyte Colony Stimulating [SP*] ¹	Factors Nivestym	Granix, Neupogen, Releuko, Zarxio
Hematopoietic Agents [SP*] ¹	Udenyca Onbody [NP] ¹ , Ziextenzo	Fulphila, Fylnetra, Neulasta, Neulasta Onpro ¹ , Nyvepria, Rolvedon, Stimufend, Udenyca
HEPATITIS		
Anti-hepatitis C (HCV) Agents [SP*] ¹	Epclusa, Harvoni, Mavyret	Ledipasvir/Sofosbuvir, Sofosbuvir/Velpatasvir, Zepatier
INFLAMMATORY		
Nonsteroidal Anti-inflammatory Agents	oxaprozin 600mg tablets	Coxanto, oxaprozin capsules
Inflammatory Agents	methotrexate, Otrexup	Rasuvo
Osteoarthritis Agents ¹	Durolane, Euflexxa, Gelsyn-3, Supartz FX	Gel-One, Genvisc, Hyalgan, Monovisc, Orthovisc, Synojoynt, Synvisc, Synvisc-One, Trivisc, Visco-3, Sodium Hyaluronate 20mg / 2mL
MISCELLANEOUS		
Allergic Rhinitis	azelastine/fluticasone, Qnasl	Ryaltris
Eosinophilic Esophagitis	budesonide susp, fluticasone HFA	Eohilia
Urea Cycle Disorder	phenburane, sodium phenylbutyrate	Olpruva, Ravicti
Urinary Antispasmodics	Gemtesa [NP], Myrbetriq, oxybutynin, oxybutynin ER, solifenacin, tolterodine, trospium	Gelnique, Toviaz

[SP] = All specialty brand drugs

¹ = Specific criteria may apply to the category

Brand drugs = Capitalized Generic drugs = lower case



2025 Abridged Formulary Select EX

Effective January 1, 2025

Excluded Medications with Covered Alternatives

THERAPEUTIC CATEGORY	FORMULARY ALTERNATIVE	FORMULARY EXCLUSION
Weight Loss Agents ¹	Saxenda, Wegovy, Zepbound	Contrave, Qsymia
ONCOLOGY		
Prostate Cancer Agents-mCRPC [SP*]	Lynparza	Akeega
OPHTHALMIC		
Dry Eye Disease	Restasis, Miebo, Xiidra	Cequa, Tyrvaya
Glaucoma	latanoprost, Lumigan, tafluprost, travoprost, Vyzulta	Iyuzeh
RESPIRATORY		
Asthma-Monoclonal Antibody [SP*] ¹	Dupixent, Fasenra, Nucala, Xolair, Tezspire	Cinqair
Cystic Fibrosis [SP*] ¹	Tobi Podhaler, tobramycin neb	Bethkis, Kitabis Pak, Tobi Neb
Inhaled Corticosteroid	Arnuity, Asmanex, Qvar	Alvesco, Flovent Diskus, Flovent HFA
Long-Acting Muscarinic Antagonist	Spiriva Respimat, tiotropium brom cap	Lonhala, Spiriva
Long-Acting Muscarinic Antagonist/ Long-Acting Beta-Agonist Combination Inhalers	Anoro Ellipta, Stiolto Respimat, Trelegy, Ellipta	Bevespi Aerosphere, Utibron Neohaler
Pulmonary Anti-Inflammatory/ Long-Acting Beta-Agonist Combination Inhalers	Advair HFA, Airsupra, Breo Ellipta, breyna, budesonide/ formoterol, Combivent, Dulera, Fluticasone/Salmeterol Diskus, Wixela Inhub	Advair Diskus, Airduo Respiclick, Airduo Digihaler, Duaklir Pressair, Fluticasone HFA, Fluticasone/Vilanterol, Symbicort
Short Acting Beta Agonist/ Rescue Inhalers	albuterol sulfate HFA	Levalbuterol Tartrate HFA, Proair Digihaler, Proair HFA, Proair Respiclick, Proventil HFA, Ventolin HFA, Xopenex

[SP] = All specialty brand drugs

¹ = Specific criteria may apply to the category

Brand drugs = Capitalized Generic drugs = lower case



2025 Abridged Formulary Select EX

Effective January 1, 2025

Step Therapies

THERAPEUTIC CATEGORY	PRIMARY TREATMENT	SECONDARY TREATMENT
Acne - Oral antibiotics	doxycycline hyclate (Vibramycin), doxycycline monohydrate (Adoxa), minocycline IR	doxycycline (Targadox), doxycycline ER, minocycline ER (Solodyn)
Advanced or Metastatic Breast Cancer [SP*] ¹	Kisqali, Kisqali Femara Pack, Verzenio	Ibrance
Antiglaucoma - Rho Kinase Inhibitors	bimatoprost, latanoprost, travoprost	Rhopressa, Rocklatan
Antidepressants	bupropion IR/ER, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, mirtazapine, paroxetine, sertraline, venlafaxine IR/ER	Auvelity
Antigout	allopurinol	febuxostat
Antipsychotics	Generic aripiprazole	Opipza
Antipsychotics	Fanapt, Invega, risperidone, Clozaril, Seroquel, Secuado, Zyprexa, Abilify, Vrylar, Caplyta, Geodon, Lybalvi, Rexulti, Latuda, haloperidol, Orap	Cobenfy
Atopic Dermatitis (topical)	clobetasol, hydrocortisone, mometasone, pimecrolimus, tacrolimus, triamcinolone	Eucrisa
Attention deficit hyperactivity disorder (ADHD)	clonidine ER 0.1 mg	Onyda XR
Attention deficit hyperactivity disorder (ADHD)	dextroamphetamine/amphetamine, lisdexamfetamine, methylphenidate	Azstarys, Jornay PM, Quillichew, Quillivant
Attention deficit hyperactivity disorder (ADHD)	Azstarys, Jornay PM	Adzenys, Cotempla, Dyanavel, Xelstrym
Attention deficit hyperactivity disorder (ADHD)	atomoxetine, clonidine ER, dexamethylphenidate, dextroamphetamine/amphetamine, guanfacine ER, methylphenidate	Qelbree
Dermatologic: Rosacea	doxycycline hyclate (Vibramycin), doxycycline monohydrate (Adoxa), minocycline IR	Oracea
Diabetes: Continuous Glucose Monitors	Insulin	Dexom G6 and G7, Freestyle Libre
Diabetes - Insulin Combination	Insulin or metformin containing products	Soliqua, Xultophy
Endocrine Agents (Testosterone), testosterone pump, testosterone topical/solution ¹	testosterone cypionate, testosterone enanthate	Androderm, Androgel, Aveed, Depo-Testosterone, Fortesta, Natesto, Testim, Testopel, Vogelxo, Xyosted
Infertility (Ovulation Induction) ¹	Novarel, Ovidrel	chorionic gonadotropin, Pregnyl
Infertility (Ovarian Stimulation) ¹	Cetrorelix, Ganirelix	Cetrotide, Fyremadel

[SP*] = All specialty brand drugs

¹ = Specific criteria may apply to the category

Brand drugs = Capitalized Generic drugs = lower case



2025 Abridged Formulary Select EX

Effective January 1, 2025

Step Therapies

THERAPEUTIC CATEGORY	PRIMARY TREATMENT	SECONDARY TREATMENT
Insomnia	generic nonbenzodiazepine hypnotic agents	Ambien, Belsomra, Dayvigo, Edular, Intermezzo, Lunesta, Quviviq, Rozerem, Zolpimist
Menopause	Estradiol	Divigel, Elestrin, Evamist
Migraine -Triptans	naratriptan, rizatriptan, oral sumatriptan, oral zolmitriptan	almotriptan, eletriptan, frovatriptan, Imitrex, Maxalt, Onzentra, sumatriptan nasal, Zomig, zolmitriptan nasal
Multiple Sclerosis [SP*] ¹	Avonex, Betaseron, Copaxone 40mg, Kesimpta, Mavenclad, Mayzent, Plegridy, Rebif, Vumerity, Zeposia [NP], generic MS biologics	Aubagio, Bafiertam, Copaxone 20mg, Extavia, Gilenya, Ponvory, Tascenso, Tecfidera
Muscle Relaxants	Baclofen, carisoprodol 350 mg, chlorzoxazone, cyclobenzaprine 5 mg and 10 mg (Flexeril), methocarbamol, orphenadrine, tizanidine	carisoprodol 250 mg, cyclobenzaprine 7.5 mg, matakalone
Nasal Steroids: Nasal Polyps	fluticasone, flunisolide, mometasone furoate	Xhance
Nasal Steroids	budesonide (Rhinocort AQ), flunisolide (Nasalar), fluticasone propionate (Flonase)	Beconase AQ, mometasone, Omnaris
Ophthalmic Steroids	dexamethasone, fluorometholone, prednisolone	clobetasol
Oral Estrogen	Estradiol	Divigel, Elestrin, Evamist
Osteoporosis - Bisphosphonates	alendronate, ibandronate	risedronate
Parkinson's Disease	carbidopa/levodopa ER	Crexont, Rytary
Philadelphia Chromosome Positive Chronic Myeloid Leukemia in Chronic Phase [SP*] ¹	imatinib, Sprycel, Tasigna	Bosulif
Topical Calcineurin Inhibitors	clobetasol, hydrocortisone, mometasone, triamcinolone	Elidel, tacrolimus

[SP*] = All specialty brand drugs

¹ = Specific criteria may apply to the category

Brand drugs = Capitalized Generic drugs = lower case



2025 Abridged Formulary Select EX

Effective January 1, 2025

Anti-Inflammatory Step Therapies- Biologic Immunomodulators [SP]*											
	Rheumatological Disorders						Dermatological Disorders		Inflammatory Bowel		Other
	Ankylosing Spondylitis	Non-Radiographic Axial Spondyloarthritis	Juvenile Idiopathic Arthritis	Psoriatic Arthritis	Rheumatoid Arthritis	Systemic Juvenile Idiopathic Arthritis	Hidradentis Suppurativa	Plaque Psoriasis	Crohn's Disease	Ulcerative Colitis	Uveitis
Step 1a	Cosentyx Enbrel	Cimzia Cosentyx	Enbrel	Cosentyx Enbrel Otezla Skyrizi Stelara Tremfya	Enbrel	Tyenne	Cosentyx	Cosentyx Enbrel Otezla Skyrizi Stelara Tremfya Sotyktu	Skyrizi Stelara	Skyrizi Stelara Tremfya	
Step 1b (Directed to ONE TNF inhibitor per label) Any TNFi listed in Step 1a or 1c or 1d	Rinvoq Tablet Xeljanz (XR)	Rinvoq Tablet	Rinvoq LQ Xeljanz	Rinvoq Tablet Rinvoq LQ Xeljanz (XR)	Rinvoq Tablet Xeljanz (XR)				Rinvoq Tablet	Rinvoq Tablet Xeljanz (XR)	
Step 1c	Simlandi Adalimumab-adaz		Simlandi Adalimumab-adaz	Simlandi Adalimumab-adaz	Simlandi Adalimumab-adaz		Simlandi Adalimumab-adaz	Simlandi Adalimumab-adaz	Simlandi Adalimumab-adaz	Simlandi Adalimumab-adaz	Simlandi Adalimumab-adaz
Step 1d (new starts require trial of ONE step 1c)	Humira		Humira	Humira	Humira		Humira	Humira	Humira	Humira	Humira
Step 2a – directed to a trial of any ONE preferred drug from 1 (a to d)			Tyenne		Tyenne		Bimzelx		Cimzia	Simponi 100mg	
Step 2b – directed to ONE step 1 agent						Ilaris Actemra					

[SP] = All specialty brand drugs
1 = Specific criteria may apply to the category



2025 Abridged Formulary Select EX

Effective January 1, 2025

Anti-Inflammatory Step Therapies- Biologic Immunomodulators [SP]*											
	Rheumatological Disorders						Dermatological Disorders		Inflammatory Bowel		Other
	Ankylosing Spondylitis	Non-Radiographic Axial Spondyloarthritis	Juvenile Idiopathic Arthritis	Psoriatic Arthritis	Rheumatoid Arthritis	Systemic Juvenile Idiopathic Arthritis	Hidradentis Suppurativa	Plaque Psoriasis	Crohn's Disease	Ulcerative Colitis	Uveitis
Step 3a – directed to TWO step 1 agents (a to d) Adalimumab-adaz/Simlandi/Humira count as one product	Cimzia Simponi 50mg Taltz Remicade Avsola Infliximab Inflectra Renflexis Simponi Aria Bimzelx	Taltz Bimzelx	Simponi Aria Kevzara Cimzia Orencia	Cimzia Orencia Simponi 50mg Simponi Aria Taltz Remicade Inflectra Renflexis Avsola Infliximab	Cimzia Kineret Orencia Simponi 50mg Simponi Aria Olumiant Kevzara Rituxan Remicade Inflectra Renflexis Avsola Truxima Infliximab Ruxience Riabni			Cimzia Ilumya Remicade Inflectra Renflexis Avsola, Infliximab	Remicade Inflectra Renflexis Avsola Tysabri Infliximab Zymfentra Entyvio	Remicade, Inflectra Renflexis Avsola Infliximab Zymfentra Velsipity Zeposia Entyvio Omvoh	
Step 3b – directed to THREE step 1 (a to d) agents			Actemra		Actemra			Taltz Bimzelx Siliq			
Step 4 – directed to FOUR step 1 (a to d) agents				Bimzelx							

[SP*] = All specialty brand drugs
1 = Specific criteria may apply to the category

NOTE: *Non-formulary/excluded (Select Ex) or non-preferred (National Ex) adalimumab products include: Amjevita, Abrilada, adalimumab-aacf, adalimumab-aaty, adalimumab-ruvk, adalimumab-adbm, adalimumab-fkjp, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Yuflyma and Yusimry. Must try and fail ONE adalimumab product PLUS TWO preferred drugs from 1a to 1b (For HS: ONE adalimumab product AND Cosentyx). Step 1 adalimumab agents include: adalimumab-adaz, Simlandi and Humira.

[SP] = All specialty brand drugs
1 = Specific criteria may apply to the category



MedImpact Healthcare Systems, Inc.

10181 Scripps Gateway Ct. San Diego, CA 92131
Phone: 800.788.2949

[ElixirSolutions.com](https://www.ElixirSolutions.com)

Copyright © 2024 MedImpact Healthcare Systems, Inc. All rights reserved.

This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

MedImpact